US7678777B2 - Composition for promoting the proliferation of Lactobacillus casei subsp. casei - Google Patents
Composition for promoting the proliferation of Lactobacillus casei subsp. casei Download PDFInfo
- Publication number
- US7678777B2 US7678777B2 US12/190,121 US19012108A US7678777B2 US 7678777 B2 US7678777 B2 US 7678777B2 US 19012108 A US19012108 A US 19012108A US 7678777 B2 US7678777 B2 US 7678777B2
- Authority
- US
- United States
- Prior art keywords
- casei
- dextran
- subsp
- composition
- jcm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 244000199866 Lactobacillus casei Species 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 235000013958 Lactobacillus casei Nutrition 0.000 title claims abstract description 11
- 230000035755 proliferation Effects 0.000 title abstract description 17
- 230000001737 promoting effect Effects 0.000 title abstract description 17
- 229920002307 Dextran Polymers 0.000 claims abstract description 67
- 210000000936 intestine Anatomy 0.000 claims abstract description 22
- 230000002062 proliferating effect Effects 0.000 claims abstract description 7
- 230000007969 cellular immunity Effects 0.000 claims description 8
- 230000004727 humoral immunity Effects 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 abstract description 25
- 230000004071 biological effect Effects 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 10
- 230000002459 sustained effect Effects 0.000 abstract description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 33
- 229940098773 bovine serum albumin Drugs 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 244000005700 microbiome Species 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000000624 ear auricle Anatomy 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000272496 Galliformes Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000423333 Bacteroides fragilis NCTC 9343 Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000186398 Eubacterium limosum Species 0.000 description 1
- 241000605975 Fusobacterium varium Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/273—Dextran; Polysaccharides produced by leuconostoc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to: a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei (hereinafter, abbreviated as “ L. casei subsp. casei ”) which is one species of lactic acid bacteria having a variety of biological activities; and the composition for promoting bacterial proliferation, which further comprises L. casei subsp. casei . More specifically, the present invention relates to: a pharmaceutical composition for enhancing biological activities, which comprises the composition for promoting bacterial proliferation; and a health food and feed for enhancing biological activities, which comprise the composition for promoting bacterial proliferation.
- microorganism formulations which are referred to as probiotics and consist of useful microorganisms such as living lactic acid bacteria for the purpose of effect of controlling intestinal function, prevention of infectious diseases, immunostimulation, or the like has been attracting attraction.
- useful microorganisms can grow and colonize in the intestine of a human being, animal, or the like. If the useful microorganisms cannot grow and colonize in the intestine, expected biological activities of the useful microorganisms cannot be obtained permanently. In order to solve such a problem, the fact is that supplying the microorganism formulation at all times is proposed and performed.
- prebiotics oligosaccharides or the like which can be utilized by useful microorganisms in probiotics
- symbiotics ones prepared by combining prebiotics and probiotics
- Those are also administered to a human being, animal, or the like for the aforementioned purpose.
- prebiotics are utilized by great many enteric bacteria other than intended bacteria, those bacteria scramble for the prebiotics in the intestine, so it is difficult to grow and colonize intended useful microorganisms selectively.
- An object of the present invention is, after ingestion of useful microorganisms referred to as probiotics to a human being, animal, or the like, to sustain a variety of biological activities originated from the useful microorganisms in a living body by selectively growing-proliferating and colonizing the microorganisms in the intestine or by selectively growing-proliferating useful indigenous microorganisms in the intestine without supplying those useful microorganisms at all times.
- L. casei subsp. casei is a species of bacteria capable of growing-proliferating by utilizing a dextran.
- L. casei subsp. casei is classified and named in Approved Lists (1980).
- the bacterium is Gram positive, indigenous to the intestine of a human being, animal, or the like, and a facultative anaerobic bacillus.
- the bacterium forms the intestinal bacterial flora together with other bacteria.
- the bacterium itself has biological activities, for example, an immunostimulating effect in the case of subcutaneous immunization.
- the bacterium has been found to enhance and maintain humoral immunity and cellular immunity.
- L. casei subsp. casei has been administered to a mouse only in the initial administration, and a dextran was then orally ingested permanently, in order to confirm whether L. casei subsp. casei can selectively grow-proliferate and colonize in the intestine of a human being, animal, or the like, and the biological activities of the bacterium can be sustained or not by oral ingestion of a dextran.
- the inventors of the present invention have found through an in vivo test that the bacterium grows-proliferates and colonizes in the intestine by utilizing the dextran, and the biological activities of the bacterium such as humoral immunity and cellular immunity are enhanced and maintained.
- a dextran itself is also known to have a variety of biological activities, and it has been confirmed that, in the case of administration of a dextran together with L. casei subsp. casei , a higher effect is maintained than that in the case of administration of only a dextran, and a synergistic effect is large.
- the present invention has been accomplished as described above.
- the gist of the present invention is as follows.
- a composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei comprising a dextran.
- composition for promoting bacterial proliferation according to (1), further comprising Lactobacillus casei subsp. casei.
- composition for promoting bacterial proliferation according to (1) wherein the dextran has a molecular weight of 2,000 to 40,000,000.
- a pharmaceutical composition comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
- a health food comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
- a feed comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
- FIG. 1 is a drawing showing an effect of a dextran on the bacterial number of L. casei subsp. casei in mouse feces.
- FIG. 2 is a drawing showing the results of enhancing humoral immunity by a dextran in the case of orally administering an antigen.
- FIG. 3 is a drawing showing the results of enhancing cellular immunity by a dextran in the case of orally administering the antigen.
- FIG. 4 is a drawing showing the results of enhancing humoral immunity by a dextran in the case of subcutaneously administering the antigen.
- FIG. 5 is a drawing showing the results of enhancing cellular immunity by a dextran in the case of subcutaneously administering the antigen.
- the composition of the present invention is a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating L. casei subsp. casei and the composition for promoting bacterial proliferation, which further comprises L. casei subsp. casei .
- Dextrans to be used in the composition of the present invention can be synthesized, prepared, or the like according to a general method that is well known to a person skilled in the art.
- culture of L. casei subsp. casei methods of preparing and drying of bacterial cells, gene recombination, and the like can be performed according to a general method that is well known to a person skilled in the art.
- a dextran is a polysaccharide which consists of glucose, which are mainly bonded with an ⁇ -1,6 bond.
- the dextrans to be used in the present invention may be commercially available dextrans or dextrans obtained by culturing bacteria selected from the group consisting of genus Leuconostoc and genus Streptococcus , for example, Leuconostoc mesenteroides , under a general condition, for example, in a sucrose-containing enriched medium.
- Each of the molecular weights of dextrans to be used in the present invention is 2,000 to 40,000,000, preferably 4,000 to 5,000,000, more preferably 4,000 to 2,000,000.
- a dextran having a molecular weight of less than 2,000 is not preferable because bacteria other than L. casei subsp. casei may proliferate.
- Examples of the dextrans to be used in the present invention include a dextran obtained by culturing the aforementioned bacteria without any treatment, and a dextran having an appropriate molecular weight obtained by further partial hydrolysis treatment of such a dextran.
- L. casei subsp. casei can be used in the form of viable cells, dried cells capable of growing-proliferating, or the like.
- L. casei subsp. casei to be used in the present invention there can be used a recombinant of L. casei subsp. casei which has at least a utilizing ability for a dextran in the composition for promoting bacterial proliferation of the present invention, in addition to a wild type.
- the recombinant is a novel bacterium in which a new biological activity is expressed by gene recombination of L. casei subsp. casei or another novel bacterium obtained by transducing a gene which participates in a dextran-utilizing ability originated from L. casei subsp. casei to another bacterium.
- the composition of the present invention is a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating L. casei subsp. casei and the composition for promoting bacterial proliferation which further comprises L. casei subsp. casei .
- the composition of the present invention can be prepared, administered, or the like according to a general method which is well known to a person skilled in the art except that the composition comprises a dextran or further comprises L. casei subsp. casei.
- the composition of the present invention may be a dextran only or a mixture of a dextran and L. casei subsp. casei .
- the composition of the present invention can be provided as a composition in the form of solid, semi-solid, or liquid containing a dextran in combination with a diluent, carrier, or the like which is pharmaceutically well known and pharmaceutically acceptable, or a composition in the form of solid, semi-solid, or liquid containing a dextran and L. casei subsp. casei .
- the composition of the present invention includes: a form in which the dextran of the present invention and L. casei subsp. casei have already been combined; and a form in which the dextran of the present invention and L.
- casei subsp. casei have been separately processed, and are combined when the composition is used.
- the amount of a diluent, carrier, or the like in the composition of the present invention is appropriately varied in accordance with a purpose or usage, and is not particularly limited. In general, the amount is, for example, about 0.1 to about 99.9% by weight, preferably about 1 to about 99% by weight, more preferably about 5 to about 95% by weight based on the weight of the composition.
- the dextran content reduces gradually due to bacterial utilization of the dextran, so simultaneous presence of them for a long time is preferably avoided. So, it is desirable that those be separately processed and packed, and the resultant products be mixed when they are ingested, or be separately ingested.
- the pharmaceutical composition of the present invention may be the composition of the present invention itself without other components.
- the composition may be one prepared in combination with a diluent, carrier, or the like, which is pharmaceutically well known and pharmaceutically acceptable, into a dosage form such as a soft capsule, hard capsule, granule, pill, powder, tablet, syrup, troche, or elixir.
- a diluent, carrier, or the like which is suitable to each dosage form, pharmaceutically well known, and pharmaceutically acceptable may further be contained.
- the pharmaceutical composition of the present invention can be used as a drug which aims at sustaining a variety of biological activities originated from L. casei subsp. casei in a living body by: selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like; or selective growth-proliferation of L. casei subsp. casei in the intestine, which is indigenous to the intestine.
- the addition amount of the composition of the present invention may be appropriately determined with reference to the description which relates to the dose and dosage cycle of the composition of the present invention described below.
- the health food of the present invention is one containing the composition of the present invention and a composition such as a food or beverage.
- the health food of the present invention includes: a form in which the composition of the present invention and a composition such as a food or beverage have already been combined; and a form in which the composition of the present invention and a composition such as a food or beverage have been separately processed, and are combined when the composition is ingested.
- a food or beverage include: confectioneries such as candy, chocolate, and biscuit; breads; noodles; beverages in the form of powder, liquid, and the like; dairy products such as yogurt.
- yogurt can be produced using such L. casei subsp. casei , and it is desirable that a dextran be mixed when they are ingested or be individually ingested.
- the feed of the present invention contains the composition of the present invention and formula feed of livestocks, fowls, fishes, pets, or the like.
- the feed of the present invention includes: a form in which the composition of the present invention and a feed composition have already been combined; and a form in which the composition of the present invention and a feed composition have been separately processed, and are combined when the composition is ingested.
- the health food or feed of the present invention can be used for sustaining a variety of biological activities originated from L. casei subsp. casei in a living body by: selective growth-proliferation and colonization of L. casei subsp. casei in the intestine of a human being, animal, or the like; or selective growth-proliferation of L. casei subsp. casei in the intestine, which is indigenous to the intestine.
- the addition amount of the composition of the present invention may be appropriately determined with reference to the description which relates to the dose and dosage cycle of the composition of the present invention described below.
- the dose of the composition of the present invention is, in terms of the dose of a dextran in the composition, 0.01 mg to 2 g/kg weight ⁇ day, preferably 0.1 mg to 1 g/kg weight ⁇ day, more preferably 1 mg to 100 mg/kg weight ⁇ day, and it is preferable that at least a composition comprising the dextran of the present invention be generally administered every day.
- L. casei subsp. casei is originally a bacterium which is indigenous to the intestine of a human being, animal, or the like, and in order to induce the reliable effects of the biological activities of L. casei subsp. casei , viable cells or dried cells capable of growing-proliferating are administered at least once, preferably at an appropriate interval. In addition, in order to induce more reliable effects, those cells may be administered every day.
- composition of the present invention can be targeted for all living beings such as mammals including a human being, aves, reptiles, fishes, crustaceans, and insects.
- lactic acid bacteria such as antitumor, antihypertension, antioxidation, antiulcer, anti-HIV, improvement of lipid metabolism, suppression of recurrent malignant tumor, antiinflammation, prevention and suppression of autoimmune disease, decrease of serum cholesterol, decrease of blood glucose, suppression of producing IgE antibody, antiallergy, promotion of producing interleukin 12, promotion of absorbing mineral, enrichment of mineral, regulation of alcohol absorption and metabolism, prevention and treatment of urinary tract infection, suppression of producing harmful matter, control of intestinal function, prevention of constipation, beauty, treatment and prevention of hyperammonemia and hepatic encephalopathy, or the like, prevention of infection, suppression of feces malodor, decrease of intestinal pH of livestocks, fowls, improvement of growth, promotion of fattening, and help of egg laying.
- Leuconostoc mesenteroides which is one species of lactic acid bacteria, was inoculated in a medium containing sucrose as a principal material (sucrose-containing enriched medium), and cultured anaerobically at 25° C. for 24 hours. Subsequently, methanol was added to the culture supernatant, and the resultant precipitates were dissolved in distilled water. After the insolubles had been removed, methanol was added thereto again, and the resultant precipitates were redissolved in distilled water. The mixture was subjected to spray drying, to thereby yield a dextran. The dextran was further partially hydrolyzed, and the resultant products were subjected to methanol fractionation and spray drying, to thereby yield dextrans having a variety of molecular weights.
- JCM 8136 plantarum casei subsp.
- JCM 1161 pseudoplantarum casei subsp.
- JCM 1136 ⁇ rhamnosus crispatus
- JCM 1185 ⁇ curvatus
- JCM 1096 delbrueckii subsp.
- JCM 1002 ⁇ bulgaricus delbrueckii subsp.
- JCM 1248 ⁇ lactis fermentum JCM 1173 ⁇ gallinarum JCM 2011 ⁇ gasseri JCM 1131 ⁇ johnsonii JCM 2012 ⁇ oris JCM 11028 ⁇ paracasei subsp.
- JCM 1053 ⁇ paracasei plantarum IFO 3070 ⁇ reuteri JCM 1112 ⁇ salivarius subsp.
- JCM 1150 ⁇ salicinius salivarius subsp.
- JCM 1231 salivarius Clostridium butyricum
- JCM 1391 ⁇ perfringens
- JCM 1290 ⁇ Klebsiella pneumoniae subsp.
- JCM 1662 ⁇ pneumoniae Fusobacterium varium JCM 3722 ⁇ Enterococcus faecalis
- JCM 5803 ⁇ faecium JCM 5804 ⁇ Eubacterium limosum
- JCM 6421 ⁇ Propionibacterium acnes
- JCM 6425 Bacteroides fragilis ATCC 25285 ⁇ Escherichia coli IFO 3972 ⁇ Bacillus subtilis subsp.
- JCM 5820 ⁇ globosum pseudolongum subsp. JCM 1205 ⁇ pseudolongum pullorum JCM 1214 ⁇ ruminantium JCM 8222 ⁇ saeculare JCM 8223 ⁇ subtile JCM 5822 ⁇ suis JCM 1269 ⁇ thermophilum JCM 1207 ⁇
- mice 12 eight-week-old BALB/c male mice were divided into two groups of six each. Those groups were referred to as (1) control group and (2) dextran group. Over the test period from the beginning of the test, a conventional feed was given to (1), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to (2). Over the period of three days from the beginning of the test, L. casei subsp. casei cells were orally inoculated to both groups (10 6 cells/mouse). On 28th day, each mouse was dissected, and the feces were collected from the large intestine.
- the feces were serially diluted with phosphate buffered saline (PBS), and the resultant mixture was smeared on a dextran-added LB medium, followed by culture at 37° C. for 48 hours. After colonies had been stained by Gram staining and observed, the bacterial number of L. casei subsp. casei in feces was counted. As a result, the bacterial number of L. casei subsp. casei in the dextran group was significantly larger than that in the control group. (See FIG. 1 )
- mice 30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA (bovine serum albumin) group, (3) BSA+ L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+ L. casei subsp. casei +dextran group.
- BSA bovine serum albumin
- BSA+dextran group BSA+ L. casei subsp. casei +dextran group.
- a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5).
- casei cells were orally inoculated to (3) and (5) (10 6 cells/mouse).
- BSA was dissolved in PBS at a concentration of 10 mg/ml, and the solution was orally administered (1 mg (100 ⁇ l)/mouse) to (2) to (5).
- BSA was orally administered (1 mg/mouse).
- the blood was drawn from the suborbital vein, and the anti-BSA antibody titer was determined by ELISA.
- the specific antibody titer was significantly high. (See FIG. 2 )
- mice 30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+ L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+ L. casei subsp. casei +dextran group.
- a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5).
- L. casei subsp. casei cells were orally inoculated to (3) and (5) (10 6 cells/mouse).
- BSA was dissolved in PBS at a concentration of 10 mg/ml, and the solution was orally administered (1 mg (100 ⁇ l)/mouse) to (2) to (5).
- BSA was orally administered (1 mg/mouse).
- Five days after the administration BSA was dissolved in PBS, and the solution was intradermally administered to the earlobe, followed by measuring the thickness of the mouse earlobe after 24, 48, and 72 hours.
- BSA+ L. casei subsp. casei +dextran group the thickness of the earlobe significantly increased. (See FIG. 3 )
- mice 30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+ L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+ L. casei subsp. casei +dextran group.
- a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) and the resultant feed was given to each of (4) and (5).
- casei bacteria cells were orally inoculated to (3) and (5) (10 6 cells/mouse).
- FIA Fluorescence-Activated adjuvant
- PBS+FIA phosphate buffered saline
- BSA+FIA BSA (5 mg/ml)
- booster was performed in a manner similar to that on the third day.
- mice 30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+ L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+ L. casei subsp. casei +dextran group.
- a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5).
- L. casei subsp. casei bacteria cells were orally inoculated to (3) and (5) (10 6 cells/mouse).
- L. casei subsp. casei a variety of biological activities originated from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like or by selectively growing-proliferating L. casei subsp. casei in the intestine, without supplying L. casei subsp. casei at all times.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Cardiology (AREA)
Abstract
A composition for promoting bacterial proliferation and selectively proliferating Lactobacillus casei subsp. casei is disclosed, which includes a dextran. A variety of biological activities originating from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like or by selectively growing-proliferating L. casei subsp. casei in the intestine, without supplying L. casei subsp. casei at all times.
Description
This application is a divisional of U.S. application Ser. No. 10/521,947, filed Feb. 24, 2005, which is the U.S. National Phase under 35 U.S.C. §371 of International Application PCT/JP2003/009272, filed Jul. 22, 2003, which was published in a language other than English, which claims priority of Japanese Patent Application No. 2002-212336, filed Jul. 22, 2002.
The present invention relates to: a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei (hereinafter, abbreviated as “L. casei subsp. casei”) which is one species of lactic acid bacteria having a variety of biological activities; and the composition for promoting bacterial proliferation, which further comprises L. casei subsp. casei. More specifically, the present invention relates to: a pharmaceutical composition for enhancing biological activities, which comprises the composition for promoting bacterial proliferation; and a health food and feed for enhancing biological activities, which comprise the composition for promoting bacterial proliferation.
Recently, ingestion of “microorganism formulations” which are referred to as probiotics and consist of useful microorganisms such as living lactic acid bacteria for the purpose of effect of controlling intestinal function, prevention of infectious diseases, immunostimulation, or the like has been attracting attraction. However, there is a doubt whether the useful microorganisms can grow and colonize in the intestine of a human being, animal, or the like. If the useful microorganisms cannot grow and colonize in the intestine, expected biological activities of the useful microorganisms cannot be obtained permanently. In order to solve such a problem, the fact is that supplying the microorganism formulation at all times is proposed and performed. On the other hand, oligosaccharides or the like which can be utilized by useful microorganisms in probiotics are referred to as prebiotics, and ones prepared by combining prebiotics and probiotics are referred to as symbiotics. Those are also administered to a human being, animal, or the like for the aforementioned purpose. However, when the prebiotics are utilized by great many enteric bacteria other than intended bacteria, those bacteria scramble for the prebiotics in the intestine, so it is difficult to grow and colonize intended useful microorganisms selectively.
An object of the present invention is, after ingestion of useful microorganisms referred to as probiotics to a human being, animal, or the like, to sustain a variety of biological activities originated from the useful microorganisms in a living body by selectively growing-proliferating and colonizing the microorganisms in the intestine or by selectively growing-proliferating useful indigenous microorganisms in the intestine without supplying those useful microorganisms at all times.
The inventors of the present invention have found out through an in vitro test that, among many useful microorganisms, L. casei subsp. casei is a species of bacteria capable of growing-proliferating by utilizing a dextran. L. casei subsp. casei is classified and named in Approved Lists (1980). The bacterium is Gram positive, indigenous to the intestine of a human being, animal, or the like, and a facultative anaerobic bacillus. The bacterium forms the intestinal bacterial flora together with other bacteria.
Thus, at first, it was confirmed whether or not the bacterium itself has biological activities, for example, an immunostimulating effect in the case of subcutaneous immunization. As a result, the bacterium has been found to enhance and maintain humoral immunity and cellular immunity. Next, L. casei subsp. casei has been administered to a mouse only in the initial administration, and a dextran was then orally ingested permanently, in order to confirm whether L. casei subsp. casei can selectively grow-proliferate and colonize in the intestine of a human being, animal, or the like, and the biological activities of the bacterium can be sustained or not by oral ingestion of a dextran. As a result, the inventors of the present invention have found through an in vivo test that the bacterium grows-proliferates and colonizes in the intestine by utilizing the dextran, and the biological activities of the bacterium such as humoral immunity and cellular immunity are enhanced and maintained.
On the other hand, a dextran itself is also known to have a variety of biological activities, and it has been confirmed that, in the case of administration of a dextran together with L. casei subsp. casei, a higher effect is maintained than that in the case of administration of only a dextran, and a synergistic effect is large.
The present invention has been accomplished as described above. The gist of the present invention is as follows.
(1) A composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei, comprising a dextran.
(2) The composition for promoting bacterial proliferation according to (1), further comprising Lactobacillus casei subsp. casei.
(3) The composition for promoting bacterial proliferation according to (1), wherein the dextran has a molecular weight of 2,000 to 40,000,000.
(4) A pharmaceutical composition comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
(5) A health food comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
(6) A feed comprising the composition for promoting bacterial proliferation according to any one of (1) to (3).
The composition of the present invention is a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating L. casei subsp. casei and the composition for promoting bacterial proliferation, which further comprises L. casei subsp. casei. Dextrans to be used in the composition of the present invention can be synthesized, prepared, or the like according to a general method that is well known to a person skilled in the art. Moreover, culture of L. casei subsp. casei, methods of preparing and drying of bacterial cells, gene recombination, and the like can be performed according to a general method that is well known to a person skilled in the art.
(Description of Dextran to be Used in the Present Invention)
A dextran is a polysaccharide which consists of glucose, which are mainly bonded with an α-1,6 bond. The dextrans to be used in the present invention may be commercially available dextrans or dextrans obtained by culturing bacteria selected from the group consisting of genus Leuconostoc and genus Streptococcus, for example, Leuconostoc mesenteroides, under a general condition, for example, in a sucrose-containing enriched medium.
(Molecular Weight of Dextran to be Used in the Present Invention)
Each of the molecular weights of dextrans to be used in the present invention is 2,000 to 40,000,000, preferably 4,000 to 5,000,000, more preferably 4,000 to 2,000,000. Note that a dextran having a molecular weight of less than 2,000 is not preferable because bacteria other than L. casei subsp. casei may proliferate. Examples of the dextrans to be used in the present invention include a dextran obtained by culturing the aforementioned bacteria without any treatment, and a dextran having an appropriate molecular weight obtained by further partial hydrolysis treatment of such a dextran.
(L. casei subsp. casei to be used in the Present Invention)
In the present invention, L. casei subsp. casei can be used in the form of viable cells, dried cells capable of growing-proliferating, or the like. As L. casei subsp. casei to be used in the present invention, there can be used a recombinant of L. casei subsp. casei which has at least a utilizing ability for a dextran in the composition for promoting bacterial proliferation of the present invention, in addition to a wild type. There can also be used a recombinant obtained by transducing a gene which participates in a dextran-utilizing ability originated from L. casei subsp. casei to another bacterium. Preferably, the recombinant is a novel bacterium in which a new biological activity is expressed by gene recombination of L. casei subsp. casei or another novel bacterium obtained by transducing a gene which participates in a dextran-utilizing ability originated from L. casei subsp. casei to another bacterium.
The composition of the present invention is a dextran-comprising composition for promoting bacterial proliferation for selectively proliferating L. casei subsp. casei and the composition for promoting bacterial proliferation which further comprises L. casei subsp. casei. The composition of the present invention can be prepared, administered, or the like according to a general method which is well known to a person skilled in the art except that the composition comprises a dextran or further comprises L. casei subsp. casei.
(Dosage Form of Composition of the Present Invention)
The composition of the present invention may be a dextran only or a mixture of a dextran and L. casei subsp. casei. Preferably, the composition of the present invention can be provided as a composition in the form of solid, semi-solid, or liquid containing a dextran in combination with a diluent, carrier, or the like which is pharmaceutically well known and pharmaceutically acceptable, or a composition in the form of solid, semi-solid, or liquid containing a dextran and L. casei subsp. casei. Note that the composition of the present invention includes: a form in which the dextran of the present invention and L. casei subsp. casei have already been combined; and a form in which the dextran of the present invention and L. casei subsp. casei have been separately processed, and are combined when the composition is used. The amount of a diluent, carrier, or the like in the composition of the present invention is appropriately varied in accordance with a purpose or usage, and is not particularly limited. In general, the amount is, for example, about 0.1 to about 99.9% by weight, preferably about 1 to about 99% by weight, more preferably about 5 to about 95% by weight based on the weight of the composition.
Note that, when a dextran and L. casei subsp. casei are simultaneously present in the form of liquid, the dextran content reduces gradually due to bacterial utilization of the dextran, so simultaneous presence of them for a long time is preferably avoided. So, it is desirable that those be separately processed and packed, and the resultant products be mixed when they are ingested, or be separately ingested.
The pharmaceutical composition of the present invention may be the composition of the present invention itself without other components. However, preferably, the composition may be one prepared in combination with a diluent, carrier, or the like, which is pharmaceutically well known and pharmaceutically acceptable, into a dosage form such as a soft capsule, hard capsule, granule, pill, powder, tablet, syrup, troche, or elixir. A method of preparing the composition into such a dosage form is well known to a person skilled in the art. When the composition is prepared into such a dosage form, a diluent, carrier, or the like which is suitable to each dosage form, pharmaceutically well known, and pharmaceutically acceptable may further be contained.
The pharmaceutical composition of the present invention can be used as a drug which aims at sustaining a variety of biological activities originated from L. casei subsp. casei in a living body by: selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like; or selective growth-proliferation of L. casei subsp. casei in the intestine, which is indigenous to the intestine.
When the pharmaceutical composition of the present invention is prepared, the addition amount of the composition of the present invention may be appropriately determined with reference to the description which relates to the dose and dosage cycle of the composition of the present invention described below.
The health food of the present invention is one containing the composition of the present invention and a composition such as a food or beverage. Note that the health food of the present invention includes: a form in which the composition of the present invention and a composition such as a food or beverage have already been combined; and a form in which the composition of the present invention and a composition such as a food or beverage have been separately processed, and are combined when the composition is ingested. Examples of such a food or beverage include: confectioneries such as candy, chocolate, and biscuit; breads; noodles; beverages in the form of powder, liquid, and the like; dairy products such as yogurt. In particular, in the case of yogurt, yogurt can be produced using such L. casei subsp. casei, and it is desirable that a dextran be mixed when they are ingested or be individually ingested.
The feed of the present invention contains the composition of the present invention and formula feed of livestocks, fowls, fishes, pets, or the like. Note that the feed of the present invention includes: a form in which the composition of the present invention and a feed composition have already been combined; and a form in which the composition of the present invention and a feed composition have been separately processed, and are combined when the composition is ingested.
The health food or feed of the present invention can be used for sustaining a variety of biological activities originated from L. casei subsp. casei in a living body by: selective growth-proliferation and colonization of L. casei subsp. casei in the intestine of a human being, animal, or the like; or selective growth-proliferation of L. casei subsp. casei in the intestine, which is indigenous to the intestine.
When the health food or feed of the present invention is prepared, the addition amount of the composition of the present invention may be appropriately determined with reference to the description which relates to the dose and dosage cycle of the composition of the present invention described below.
(Dose and Dosage Cycle of Composition of the Present Invention)
The dose of the composition of the present invention is, in terms of the dose of a dextran in the composition, 0.01 mg to 2 g/kg weight·day, preferably 0.1 mg to 1 g/kg weight·day, more preferably 1 mg to 100 mg/kg weight·day, and it is preferable that at least a composition comprising the dextran of the present invention be generally administered every day. Note that L. casei subsp. casei is originally a bacterium which is indigenous to the intestine of a human being, animal, or the like, and in order to induce the reliable effects of the biological activities of L. casei subsp. casei, viable cells or dried cells capable of growing-proliferating are administered at least once, preferably at an appropriate interval. In addition, in order to induce more reliable effects, those cells may be administered every day.
(Applicable Target of Composition of the Present Invention)
The composition of the present invention can be targeted for all living beings such as mammals including a human being, aves, reptiles, fishes, crustaceans, and insects.
(Biological Activity Expected to be Imparted and/or Improved by Composition of the Present Invention)
The following effects are expected: in addition to an immunostimulating effect, generally mentioned biological activities of lactic acid bacteria such as antitumor, antihypertension, antioxidation, antiulcer, anti-HIV, improvement of lipid metabolism, suppression of recurrent malignant tumor, antiinflammation, prevention and suppression of autoimmune disease, decrease of serum cholesterol, decrease of blood glucose, suppression of producing IgE antibody, antiallergy, promotion of producing interleukin 12, promotion of absorbing mineral, enrichment of mineral, regulation of alcohol absorption and metabolism, prevention and treatment of urinary tract infection, suppression of producing harmful matter, control of intestinal function, prevention of constipation, beauty, treatment and prevention of hyperammonemia and hepatic encephalopathy, or the like, prevention of infection, suppression of feces malodor, decrease of intestinal pH of livestocks, fowls, improvement of growth, promotion of fattening, and help of egg laying.
Hereinafter, the present invention is described in more detail by way of examples, but the present invention is not limited thereto.
Leuconostoc mesenteroides, which is one species of lactic acid bacteria, was inoculated in a medium containing sucrose as a principal material (sucrose-containing enriched medium), and cultured anaerobically at 25° C. for 24 hours. Subsequently, methanol was added to the culture supernatant, and the resultant precipitates were dissolved in distilled water. After the insolubles had been removed, methanol was added thereto again, and the resultant precipitates were redissolved in distilled water. The mixture was subjected to spray drying, to thereby yield a dextran. The dextran was further partially hydrolyzed, and the resultant products were subjected to methanol fractionation and spray drying, to thereby yield dextrans having a variety of molecular weights.
A variety of related enteric bacteria were inoculated in a PYF medium (Peptone yeast extract Fildes solution broth) to which a dextran having a molecular weight (number average) of 10,000 (in the following examples, a dextran having such a molecular weight was used unless otherwise defined) was added to 0.5%, and the dextran-utilizing ability was determined. As a result, two strains of L. casei subsp. casei (JCM 1134 and JCM 8129) were confirmed to have the dextran-utilizing ability. However, no dextran-utilizing ability was observed for other lactic acid bacteria such as bacteria of the genus Lactobacillus or Bifidobacterium, and other related enteric bacteria. (See Table 1)
| TABLE 1 |
| Dextran-utilizing ability of related enteric bacteria |
| Bacterial | Dextran- | |
| strain | utilizing | |
| Bacterial name | name | ability |
| Lactobacillus | casei subsp. | JCM 1134 | + |
| casei | |||
| casei subsp. | JCM 8129 | + | |
| casei | |||
| acidophilus | #527 | − | |
| acidophilus | JCM 1132 | − | |
| agilis | JCM 1187 | − | |
| amylovorus | JCM 1126 | − | |
| aviarius subsp. | JCM 5666 | − | |
| aviarius | |||
| brevis | JCM 1059 | − | |
| buchneri | JCM 1115 | − | |
| casei subsp. | JCM 1133 | − | |
| alactosus | |||
| casei subsp. | JCM 1177 | − | |
| fusiformis | |||
| casei subsp. | JCM 8136 | − | |
| plantarum | |||
| casei subsp. | JCM 1161 | − | |
| pseudoplantarum | |||
| casei subsp. | JCM 1136 | − | |
| rhamnosus | |||
| crispatus | JCM 1185 | − | |
| curvatus | JCM 1096 | − | |
| delbrueckii subsp. | JCM 1002 | − | |
| bulgaricus | |||
| delbrueckii subsp. | JCM 1248 | − | |
| lactis | |||
| fermentum | JCM 1173 | − | |
| gallinarum | JCM 2011 | − | |
| gasseri | JCM 1131 | − | |
| johnsonii | JCM 2012 | − | |
| oris | JCM 11028 | − | |
| paracasei subsp. | JCM 1053 | − | |
| paracasei | |||
| plantarum | IFO 3070 | − | |
| reuteri | JCM 1112 | − | |
| salivarius subsp. | JCM 1150 | − | |
| salicinius | |||
| salivarius subsp. | JCM 1231 | − | |
| salivarius | |||
| Clostridium | butyricum | JCM 1391 | − |
| perfringens | JCM 1290 | − | |
| Klebsiella | pneumoniae subsp. | JCM 1662 | − |
| pneumoniae | |||
| Fusobacterium | varium | JCM 3722 | − |
| Enterococcus | faecalis | JCM 5803 | − |
| faecium | JCM 5804 | − | |
| Eubacterium | limosum | JCM 6421 | − |
| Propionibacterium | acnes | JCM 6425 | − |
| Bacteroides | fragilis | ATCC 25285 | − |
| Escherichia | coli | IFO 3972 | − |
| Bacillus | subtilis subsp. | IFO 3134 | − |
| subtilis | |||
| Bifidobacterium | adolescentis | JCM 1275 | − |
| angulatum | JCM 7096 | − | |
| animalis | JCM 1190 | − | |
| asteroides | JCM 8230 | − | |
| bifidum | JCM 1209 | − | |
| boum | JCM 1211 | − | |
| breve | JCM 1192 | − | |
| catenulatum | JCM 1194 | − | |
| choerinum | JCM 1212 | − | |
| coryneforme | JCM 5819 | − | |
| cuniculi | JCM 1213 | − | |
| dentium | JCM 1195 | − | |
| gallicum | JCM 8224 | − | |
| gallinarum | JCM 6291 | − | |
| indicum | JCM 1302 | − | |
| infantis | JCM 1222 | − | |
| longum | JCM 1217 | − | |
| magnum | JCM 1218 | − | |
| merycicum | JCM 8219 | − | |
| minimum | JCM 5821 | − | |
| pseudocatenulatum | JCM 1200 | − | |
| pseudolongum subsp. | JCM 5820 | − | |
| globosum | |||
| pseudolongum subsp. | JCM 1205 | − | |
| pseudolongum | |||
| pullorum | JCM 1214 | − | |
| ruminantium | JCM 8222 | − | |
| saeculare | JCM 8223 | − | |
| subtile | JCM 5822 | − | |
| suis | JCM 1269 | − | |
| thermophilum | JCM 1207 | − | |
Moreover, using two strains of L. casei subsp. casei, a difference of the utilizing abilities according to dextrans having different molecular weights was determined. As a result, for all tested dextrans, the dextran-utilizing abilities were confirmed. However, a dextran having a smaller molecular weight has a tendency to be more utilized. (See Table 2)
| TABLE 2 |
| Difference of utilizing ability |
| according to dextran molecular weight |
| Dextran | L. casei subsp. casei |
| Molecular weight | JCM 1134 | JCM 8129 |
| 2,000 | +++ | +++ |
| 4,000 | +++ | +++ |
| 7,000 | ++ | ++ |
| 10,000 | ++ | ++ |
| 14,000 | ++ | ++ |
| 40,000 | ++ | ++ |
| 200,000 | + | + |
| 2,000,000 | + | + |
12 eight-week-old BALB/c male mice were divided into two groups of six each. Those groups were referred to as (1) control group and (2) dextran group. Over the test period from the beginning of the test, a conventional feed was given to (1), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to (2). Over the period of three days from the beginning of the test, L. casei subsp. casei cells were orally inoculated to both groups (106 cells/mouse). On 28th day, each mouse was dissected, and the feces were collected from the large intestine. The feces were serially diluted with phosphate buffered saline (PBS), and the resultant mixture was smeared on a dextran-added LB medium, followed by culture at 37° C. for 48 hours. After colonies had been stained by Gram staining and observed, the bacterial number of L. casei subsp. casei in feces was counted. As a result, the bacterial number of L. casei subsp. casei in the dextran group was significantly larger than that in the control group. (See FIG. 1 )
30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA (bovine serum albumin) group, (3) BSA+L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+L. casei subsp. casei+dextran group. Over the test period from the beginning of the test, a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5). Over the period of three days from the beginning of the test, L. casei subsp. casei cells were orally inoculated to (3) and (5) (106 cells/mouse). On third and forth days, BSA was dissolved in PBS at a concentration of 10 mg/ml, and the solution was orally administered (1 mg (100 μl)/mouse) to (2) to (5). On 33rd and 34th days, in a manner similar to that on the third and forth days, BSA was orally administered (1 mg/mouse). Five days after the administration, the blood was drawn from the suborbital vein, and the anti-BSA antibody titer was determined by ELISA. As a result, in (5) BSA+L. casei subsp. casei+dextran group, the specific antibody titer was significantly high. (See FIG. 2 )
30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+L. casei subsp. casei+dextran group. Over the test period from the beginning of the test, a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5). Over the period of three days from the beginning of the test, L. casei subsp. casei cells were orally inoculated to (3) and (5) (106 cells/mouse). On third and forth days, BSA was dissolved in PBS at a concentration of 10 mg/ml, and the solution was orally administered (1 mg (100 μl)/mouse) to (2) to (5). On 33rd and 34th days, in a manner similar to that on the third and forth days, BSA was orally administered (1 mg/mouse). Five days after the administration, BSA was dissolved in PBS, and the solution was intradermally administered to the earlobe, followed by measuring the thickness of the mouse earlobe after 24, 48, and 72 hours. As a result, in (5) BSA+L. casei subsp. casei+dextran group, the thickness of the earlobe significantly increased. (See FIG. 3 )
30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+L. casei subsp. casei+dextran group. Over the test period from the beginning of the test, a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) and the resultant feed was given to each of (4) and (5). Over the period of three days from the beginning of the test, L. casei subsp. casei bacteria cells were orally inoculated to (3) and (5) (106 cells/mouse). On a third day, using FIA (Freund's incomplete adjuvant), PBS (phosphate buffered saline) (PBS+FIA) or BSA (5 mg/ml) (BSA+FIA) was emulsified at a ratio of 1:1, and the emulsion of PBS+FIA was subcutaneously administered to the footpads of the (1) and the emulsion of BSA+FIA was subcutaneously administered to those of the (2) to (5), respectively (200 μl/mouse). On a 35th day, booster was performed in a manner similar to that on the third day. Five days after the booster, the blood was drawn from the suborbital vein, and the anti-BSA antibody titer was determined by ELISA. As a result, in (5) BSA+L. casei subsp. casei+dextran group, the specific antibody titer was significantly high. (See FIG. 4 )
30 eight-week-old BALB/c male mice were divided into five groups of six each. Those groups were referred to as (1) control group, (2) BSA group, (3) BSA+L. casei subsp. casei group, (4) BSA+dextran group, and (5) BSA+L. casei subsp. casei+dextran group. Over the test period from the beginning of the test, a conventional feed was given to each of (1), (2), and (3), while a dextran-added conventional feed (75 mg dextran/kg conventional feed) was given to each of (4) and (5). Over the period of three days from the beginning of the test, L. casei subsp. casei bacteria cells were orally inoculated to (3) and (5) (106 cells/mouse). On a third day, using FIA, PBS (PBS+FIA) or BSA (5 mg/ml) (BSA+FIA) was emulsified at a ratio of 1:1, and the emulsion of PBS+FIA was subcutaneously administered to the footpads of the (1) and the emulsion of BSA+FIA was subcutaneously administered to those of the (2) to (5), respectively (200 μl/mouse). On a 35th day, booster was performed in a manner similar to that on the third day. Five days after the booster, BSA was dissolved in PBS, and the solution was intradermally administered to the mouse earlobe, followed by measuring the thickness of the earlobe after 24, 48, and 72 hours. As a result, in (5) BSA+L. casei subsp. casei+dextran group, the thickness of the earlobe significantly increased. (See FIG. 5 )
According to the present invention, a variety of biological activities originated from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing L. casei subsp. casei in the intestine of a human being, animal, or the like or by selectively growing-proliferating L. casei subsp. casei in the intestine, without supplying L. casei subsp. casei at all times.
Claims (4)
1. A method for selectively proliferating Lactobacillus casei subsp. casei in the intestine of a subject, comprising:
orally administering a composition consisting essentially of a dextran and Lactobacillus casei subsp. casei to the subject, whereby Lactobacillus casei subsp. casei is proliferated in the intestine of the subject.
2. The method according to claim 1 , wherein the dextran has a molecular weight of 2,000 to 40,000,000.
3. A method for enhancing humoral and cellular immunity in a subject in need thereof, comprising:
selectively proliferating Lactobacillus casei subsp. casei in the intestine of the subject by orally administering a pharmaceutical composition consisting essentially of a dextran and Lactobacillus casei subsp. casei to the subject, whereby humoral and cellular immunity are enhanced.
4. The method according to claim 3 , wherein the dextran has a molecular weight of 2,000 to 40,000,000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/190,121 US7678777B2 (en) | 2002-07-22 | 2008-08-12 | Composition for promoting the proliferation of Lactobacillus casei subsp. casei |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-212336 | 2002-07-22 | ||
| JP2002212336 | 2002-07-22 | ||
| US10/521,947 US20060127378A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| PCT/JP2003/009272 WO2004009800A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| US12/190,121 US7678777B2 (en) | 2002-07-22 | 2008-08-12 | Composition for promoting the proliferation of Lactobacillus casei subsp. casei |
Related Parent Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2003/009272 Division WO2004009800A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| US10/521,947 Division US20060127378A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| US10521947 Division | 2003-07-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20080305090A1 US20080305090A1 (en) | 2008-12-11 |
| US7678777B2 true US7678777B2 (en) | 2010-03-16 |
Family
ID=30767803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/521,947 Abandoned US20060127378A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| US12/190,121 Expired - Fee Related US7678777B2 (en) | 2002-07-22 | 2008-08-12 | Composition for promoting the proliferation of Lactobacillus casei subsp. casei |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/521,947 Abandoned US20060127378A1 (en) | 2002-07-22 | 2003-07-22 | Composition for promoting the proliferation of lactobacillus casei subsp. casei |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060127378A1 (en) |
| EP (1) | EP1541672B1 (en) |
| JP (1) | JP4498924B2 (en) |
| AT (1) | ATE421990T1 (en) |
| AU (1) | AU2003281529B2 (en) |
| CA (1) | CA2493644C (en) |
| DE (1) | DE60326049D1 (en) |
| ES (1) | ES2321602T3 (en) |
| WO (1) | WO2004009800A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10195409B2 (en) | 2013-03-15 | 2019-02-05 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
| US10238848B2 (en) | 2007-04-16 | 2019-03-26 | Corium International, Inc. | Solvent-cast microprotrusion arrays containing active ingredient |
| US10245422B2 (en) | 2013-03-12 | 2019-04-02 | Corium International, Inc. | Microprojection applicators and methods of use |
| US10384046B2 (en) | 2013-03-15 | 2019-08-20 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
| US10384045B2 (en) | 2013-03-15 | 2019-08-20 | Corium, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| US10624843B2 (en) | 2014-09-04 | 2020-04-21 | Corium, Inc. | Microstructure array, methods of making, and methods of use |
| US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
| US11052231B2 (en) | 2012-12-21 | 2021-07-06 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
| US11419816B2 (en) | 2010-05-04 | 2022-08-23 | Corium, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2520483B (en) * | 2013-11-15 | 2017-06-07 | Genmont Biotech Inc | A probiotic composition for treating picornavirus infection and its use thereof |
| CN117467584B (en) * | 2023-12-27 | 2024-03-29 | 山东威曼宠物食品有限公司 | A compound probiotic agent for improving cat intestinal health, preparation method and application |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382355A2 (en) | 1989-02-09 | 1990-08-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Growth promoting agent for bacteria containing pullulan and/or dextran |
| JPH06217761A (en) | 1992-06-18 | 1994-08-09 | Nisshin Flour Milling Co Ltd | Growth promoter for enteral useful bacteria |
| JPH08196268A (en) | 1995-01-24 | 1996-08-06 | Lotte Co Ltd | Growth promoter for lactic acid bacteria |
| EP0726272A2 (en) | 1995-02-10 | 1996-08-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Non-reducing saccharides, their preparations and uses |
| US6007808A (en) * | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
| JP2000270784A (en) | 1999-03-29 | 2000-10-03 | Nihon Nosan Kogyo Kk | Feed for cattle and poultry |
| JP2001269125A (en) | 2000-03-29 | 2001-10-02 | Nihon Nosan Kogyo Kk | Feed for pig |
-
2003
- 2003-07-22 US US10/521,947 patent/US20060127378A1/en not_active Abandoned
- 2003-07-22 WO PCT/JP2003/009272 patent/WO2004009800A1/en active Application Filing
- 2003-07-22 JP JP2004522778A patent/JP4498924B2/en not_active Expired - Fee Related
- 2003-07-22 CA CA2493644A patent/CA2493644C/en not_active Expired - Fee Related
- 2003-07-22 AU AU2003281529A patent/AU2003281529B2/en not_active Ceased
- 2003-07-22 EP EP03741533A patent/EP1541672B1/en not_active Expired - Lifetime
- 2003-07-22 ES ES03741533T patent/ES2321602T3/en not_active Expired - Lifetime
- 2003-07-22 AT AT03741533T patent/ATE421990T1/en not_active IP Right Cessation
- 2003-07-22 DE DE60326049T patent/DE60326049D1/en not_active Expired - Lifetime
-
2008
- 2008-08-12 US US12/190,121 patent/US7678777B2/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382355A2 (en) | 1989-02-09 | 1990-08-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Growth promoting agent for bacteria containing pullulan and/or dextran |
| JPH02289520A (en) | 1989-02-09 | 1990-11-29 | Hayashibara Biochem Lab Inc | Multiplication promoter of lactobacillus bifidus |
| JPH06217761A (en) | 1992-06-18 | 1994-08-09 | Nisshin Flour Milling Co Ltd | Growth promoter for enteral useful bacteria |
| JPH08196268A (en) | 1995-01-24 | 1996-08-06 | Lotte Co Ltd | Growth promoter for lactic acid bacteria |
| EP0726272A2 (en) | 1995-02-10 | 1996-08-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Non-reducing saccharides, their preparations and uses |
| US6007808A (en) * | 1995-06-23 | 1999-12-28 | Dibra S.P.A. | Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders |
| JP2000270784A (en) | 1999-03-29 | 2000-10-03 | Nihon Nosan Kogyo Kk | Feed for cattle and poultry |
| JP2001269125A (en) | 2000-03-29 | 2001-10-02 | Nihon Nosan Kogyo Kk | Feed for pig |
Non-Patent Citations (5)
| Title |
|---|
| Office Action mailed Jun. 6, 2006 issued to a corresponding Japanese application (2004-522778) with English translation. |
| Ogawa, et al. "A New Synbiotic, Lactobacillus casei subsp. casei Together with Dextran, Reduces Murine and Human Allergic Reaction," FEMS Immunology and Medical Microbiology, vol. 46, No. 3, pp. 400-409, Apr. 2006. |
| Ogawa, et al. "Dextran Tokui Shikasei Nyusankin o Mochiita Synbiotics ni yoru Keiko-Teki Men, Eki Zokyo Sayo," Japanese Journal of Bacteriology, vol. 58, No. 1, Feb. 28, 2003 with partial English translation. |
| Ogawa, et al. "Natural Kill Cell Activities of Synbiotic Lactobacillus casei ssp. casei in Conjunction with Dextran," Clinical and Experimental Immunology, vol. 143, No. 1, pp. 103-109, Jan. 2006. |
| Supplementary European Search Report dated Apr. 25, 2006. |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10238848B2 (en) | 2007-04-16 | 2019-03-26 | Corium International, Inc. | Solvent-cast microprotrusion arrays containing active ingredient |
| US11419816B2 (en) | 2010-05-04 | 2022-08-23 | Corium, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
| US11052231B2 (en) | 2012-12-21 | 2021-07-06 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
| US10245422B2 (en) | 2013-03-12 | 2019-04-02 | Corium International, Inc. | Microprojection applicators and methods of use |
| US11110259B2 (en) | 2013-03-12 | 2021-09-07 | Corium, Inc. | Microprojection applicators and methods of use |
| US10195409B2 (en) | 2013-03-15 | 2019-02-05 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
| US10384046B2 (en) | 2013-03-15 | 2019-08-20 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
| US10384045B2 (en) | 2013-03-15 | 2019-08-20 | Corium, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
| US11565097B2 (en) | 2013-03-15 | 2023-01-31 | Corium Pharma Solutions, Inc. | Microarray for delivery of therapeutic agent and methods of use |
| US10624843B2 (en) | 2014-09-04 | 2020-04-21 | Corium, Inc. | Microstructure array, methods of making, and methods of use |
| US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1541672B1 (en) | 2009-01-28 |
| JP4498924B2 (en) | 2010-07-07 |
| AU2003281529B2 (en) | 2008-01-17 |
| JPWO2004009800A1 (en) | 2005-11-17 |
| DE60326049D1 (en) | 2009-03-19 |
| US20080305090A1 (en) | 2008-12-11 |
| US20060127378A1 (en) | 2006-06-15 |
| AU2003281529A1 (en) | 2004-02-09 |
| ATE421990T1 (en) | 2009-02-15 |
| WO2004009800A1 (en) | 2004-01-29 |
| ES2321602T3 (en) | 2009-06-09 |
| EP1541672A1 (en) | 2005-06-15 |
| EP1541672A4 (en) | 2006-06-14 |
| CA2493644A1 (en) | 2004-01-29 |
| CA2493644C (en) | 2012-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678777B2 (en) | Composition for promoting the proliferation of Lactobacillus casei subsp. casei | |
| US11225641B2 (en) | Probiotic Bifidobacterium strain | |
| KR102624867B1 (en) | Bifidobacterium breve 207-1 and uses thereof | |
| CN114032193B (en) | Lactobacillus paracasei 207-27 and application thereof | |
| RU2466185C2 (en) | PROBIOTIC STRAIN Bifidobacterium longum, PROBIOTIC COMPOSITION AND USE OF STRAIN Bifidobacterium longum | |
| US8557233B2 (en) | Probiotic bifidobacterium strains | |
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| KR102024883B1 (en) | Lactobacillus Fermentum KBL 375 and Use Thereof | |
| CN101626774A (en) | Composition for improving intestinal microflora | |
| TW202022109A (en) | Novel bacterial strain of lactobacillus and immunostimulant comprising the same | |
| US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
| BG112471A (en) | Immunomodulating synbiotic composition | |
| JP2007112805A (en) | Composition for promoting propagation of lactobacillus casei subsp. casei |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.) |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180316 |